Antagonism between bacteriostatic and bactericidal antibiotics is prevalent PS Ocampo, V Lázár, B Papp, M Arnoldini, P Abel zur Wiesch, ... Antimicrobial agents and chemotherapy 58 (8), 4573-4582, 2014 | 329 | 2014 |
Population biological principles of drug-resistance evolution in infectious diseases PA Zur Wiesch, R Kouyos, J Engelstädter, RR Regoes, S Bonhoeffer The Lancet infectious diseases 11 (3), 236-247, 2011 | 297 | 2011 |
Compensation of fitness costs and reversibility of antibiotic resistance mutations P Schulz zur Wiesch, J Engelstadter, S Bonhoeffer Antimicrobial agents and chemotherapy 54 (5), 2085-2095, 2010 | 209 | 2010 |
Bi-modal Distribution of the Second Messenger c-di-GMP Controls Cell Fate and Asymmetry during the Caulobacter Cell Cycle S Abel, T Bucher, M Nicollier, I Hug, V Kaever, P Abel zur Wiesch, U Jenal PLoS genetics 9 (9), e1003744, 2013 | 151 | 2013 |
Analysis of bottlenecks in experimental models of infection S Abel, P Abel zur Wiesch, BM Davis, MK Waldor PLoS pathogens 11 (6), e1004823, 2015 | 138 | 2015 |
Genetic analysis of Vibrio parahaemolyticus intestinal colonization TP Hubbard, MC Chao, S Abel, CJ Blondel, P Abel zur Wiesch, X Zhou, ... Proceedings of the National Academy of Sciences 113 (22), 6283-6288, 2016 | 119 | 2016 |
The path of least resistance: aggressive or moderate treatment? RD Kouyos, CJE Metcalf, R Birger, EY Klein, P Abel zur Wiesch, ... Proceedings of the Royal Society B: Biological Sciences 281 (1794), 20140566, 2014 | 112 | 2014 |
Sequence tag–based analysis of microbial population dynamics S Abel, P Abel zur Wiesch, HH Chang, BM Davis, M Lipsitch, MK Waldor Nature methods 12 (3), 223-226, 2015 | 108 | 2015 |
Cycling empirical antibiotic therapy in hospitals: meta-analysis and models P Abel zur Wiesch, R Kouyos, S Abel, W Viechtbauer, S Bonhoeffer PLoS pathogens 10 (6), e1004225, 2014 | 97 | 2014 |
Smear positivity in paediatric and adult tuberculosis: systematic review and meta-analysis A Kunkel, P Abel zur Wiesch, RR Nathavitharana, FM Marx, HE Jenkins, ... BMC infectious diseases 16, 1-9, 2016 | 88 | 2016 |
Deciphering the landscape of host barriers to Listeria monocytogenes infection T Zhang, S Abel, P Abel zur Wiesch, J Sasabe, BM Davis, DE Higgins, ... Proceedings of the National Academy of Sciences 114 (24), 6334-6339, 2017 | 86 | 2017 |
Classic reaction kinetics can explain complex patterns of antibiotic action P Abel zur Wiesch, S Abel, S Gkotzis, P Ocampo, J Engelstädter, ... Science translational medicine 7 (287), 287ra73-287ra73, 2015 | 85 | 2015 |
On being the right size: the impact of population size and stochastic effects on the evolution of drug resistance in hospitals and the community RD Kouyos, P Abel zur Wiesch, S Bonhoeffer PLoS pathogens 7 (4), e1001334, 2011 | 50 | 2011 |
Informed switching strongly decreases the prevalence of antibiotic resistance in hospital wards RD Kouyos, P Abel zur Wiesch, S Bonhoeffer PLoS computational biology 7 (3), e1001094, 2011 | 49 | 2011 |
Fitness Costs of Drug Resistance Mutations in Multidrug-Resistant Mycobacterium tuberculosis: A Household-Based Case-Control Study PP Salvatore, MC Becerra, P Abel zur Wiesch, T Hinkley, D Kaur, ... The Journal of infectious diseases 213 (1), 149-155, 2016 | 48 | 2016 |
Transposon-insertion sequencing screens unveil requirements for EHEC growth and intestinal colonization AR Warr, TP Hubbard, D Munera, CJ Blondel, P Abel zur Wiesch, S Abel, ... PLoS pathogens 15 (8), e1007652, 2019 | 45 | 2019 |
The Role of Adherence and Retreatment in De Novo Emergence of MDR-TB D Cadosch, P Abel zur Wiesch, R Kouyos, S Bonhoeffer PLoS computational biology 12 (3), e1004749, 2016 | 37 | 2016 |
Using chemical reaction kinetics to predict optimal antibiotic treatment strategies P Abel zur Wiesch, F Clarelli, T Cohen PLoS computational biology 13 (1), e1005321, 2017 | 30 | 2017 |
All nonadherence is equal but is some more equal than others? Tuberculosis in the digital era HR Stagg, M Flook, A Martinecz, K Kielmann, PA Zur Wiesch, AS Karat, ... ERJ Open Research 6 (4), 2020 | 24 | 2020 |
Multi-scale modeling of drug binding kinetics to predict drug efficacy F Clarelli, J Liang, A Martinecz, I Heiland, P Abel zur Wiesch Cellular and Molecular Life Sciences 77, 381-394, 2020 | 23 | 2020 |